{"id":15301,"date":"2026-02-13T16:17:12","date_gmt":"2026-02-13T15:17:12","guid":{"rendered":"https:\/\/www.cbd.fr\/blog\/?p=15301"},"modified":"2026-02-13T16:17:14","modified_gmt":"2026-02-13T15:17:14","slug":"cbd-what-the-anses-2025-proposal-changes-for-brands-and-customers","status":"publish","type":"post","link":"https:\/\/www.cbd.fr\/blog\/en\/cbd-what-the-anses-2025-proposal-changes-for-brands-and-customers\/","title":{"rendered":"CBD: What the ANSES 2025 proposal changes for brands and customers"},"content":{"rendered":"

By 2025, the CBD sector in France is poised to reach a new milestone with the recent guidelines from ANSES (the French Agency for Food, Environmental and Occupational Health & Safety). This proposal aims to classify cannabidiol as a substance toxic to human reproduction, thus significantly altering the legal framework and the commercial future of CBD products. Between strengthened health and safety measures, regulatory uncertainties, and evolving legislation, both producers and consumers are questioning the consequences. What concrete steps can be taken from these announcements? How does this reclassification affect the market, buyer safety, and consumer rights? Here is a detailed overview of the main aspects of the proposal. Context and Scope of the ANSES Proposal<\/strong> ANSES, the French agency responsible for health and safety, presented its proposal in early 2024 to establish a new toxicity classification for certain molecules derived from hemp, including CBD. This approach doesn’t just concern the pure substance: it directly impacts the marketing, formulation, and even communication surrounding CBD products. <\/strong>The stated objective is to protect the population from any potential risks related to toxicity to human reproduction. This direction implies a profound overhaul of CBD regulations in France. The usual distinction between natural and synthetic derivatives could evolve, complicating the legal framework governing the CBD sector. <\/strong>What changes are coming to CBD regulations? The ANSES proposal initiates a shift towards increased monitoring of permitted THC<\/a> levels, as well as enhanced vigilance across the entire CBD distribution chain. To delve deeper into the legal status of this molecule, it is relevant to refer to the detailed analyses on<\/strong> The fact that CBD is not considered a medicine under current legislation. <\/strong>This tightening of the legal framework translates into the implementation of new requirements: mandatory warnings, additional labeling constraints, and possible restrictions on certain formats (for example, highly concentrated oils). The administrative procedures required to obtain or renew a commercial authorization are expected to increase, complicating the daily operations of those involved in the CBD industry.<\/p>\n\n

<\/h2>\n

Strengthening health controls on manufacturing batches<\/strong>Requirement to indicate potential toxicity to human reproduction Systematic review of cannabinoid-rich formulations<\/strong> Impacts on the CBD industry in France The CBD industry will have to fundamentally rethink its structure. Producers, importers, and distributors will have to guarantee exemplary traceability to meet the new standards. This often involves reviewing internal processes, but also investing in additional tools for analyzing THC levels and contaminants. Several players are already anticipating this shift: expanding their ranges of low-CBD products, specializing in clean-label extraction, or using independent certifications to reassure customers about the safety of their products.<\/strong> Influence of the toxic classification on innovation Technical innovation is also under new pressure. Many R&D teams are now seeking to design CBD-based products with concentrations that comply with future recommended limits. Particular emphasis is being placed on food and cosmetic preparations intended for vulnerable populations, such as pregnant women or those with underlying health conditions, who could be denied access to CBD if the toxic classification were applied indiscriminately.<\/strong>While this unstable context may slow down some innovative projects, it also stimulates experimentation with synergies between different plant extracts, limiting direct exposure to pure cannabidiol. <\/strong>It’s important to remember that CBD is generally not classified as a medicine by the authorities, except in specific cases, which raises important questions about the boundary between cosmetics, food supplements, and therapeutic use; an aspect analyzed in detail on the recognition of CBD as a medicine under different regulatory contexts. <\/strong>Consequences for consumers: what rights, what guarantees?<\/p>\n

Consumer rights regarding CBD are directly affected by the need to ensure safe use and a transparent level of information. If the proposal is adopted, instructions for use will have to include explicit statements about toxicity to human reproduction, following a logic similar to that of conventional pharmaceutical products. Enhanced vigilance will govern the dispensing of CBD-based products in physical stores and online. To ensure the safety of their purchases, individuals should prioritize products with official labels or certificates of analysis. Certain formats may also be restricted for specific groups, particularly pregnant or breastfeeding women. <\/strong>Enhanced labeling regarding reproductive toxicity<\/strong> Priority access to factual information on the exact composition of products<\/strong> Right to a refund or withdrawal in case of proven non-compliance<\/strong>Towards harmonized legislation?<\/p>\n\n

\n
\n

Sommaire<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n